14
Participants
Start Date
September 22, 2021
Primary Completion Date
October 31, 2023
Study Completion Date
May 13, 2024
Camsirubicin
The dose escalation of camsirubicin will start at 265 mg/m2, with dose increments of 50% until a Grade 2 non-hematologic toxicity is observed at which point subsequent dose escalations will be in increments of 25% until an MTD is identified in patients with ASTS.
Sarcoma Oncology Center, Santa Monica
University of Washington Medicine Fred Hutchinson Cancer Center, Seattle
Lead Sponsor
Monopar Therapeutics
INDUSTRY